|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on January 30, 2003; DOI 10.1182/blood-2002-10-3027.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Physiology, the
Department of Pharmacology, and The Sol Sherry Thrombosis Research
Center, Temple University School of Medicine, Philadelphia,
PA.
Human platelets express 2 G protein-coupled nucleotide
receptors: the platelet adenosine diphosphate (ADP)
receptor coupled to stimulation of phospholipase C
(P2Y1) via heterotrimeric guanosine 5-triphosphate
(GTP)-binding protein Gq, and the platelet ADP receptor coupled to inhibition of adenylyl cyclase
(P2Y12) via heterotrimeric GTP-binding protein
Gi. Although these 2 receptors are encoded on the
same chromosome and have similar pharmacologic profiles, they have
different reactivities toward thiol reagents. The thiol agent
p-chloromercuribenzene sulfonic acid (pCMBS) and the active metabolites
from antiplatelet drugs, clopidogrel and CS-747, inactivate the
P2Y12 receptor and are predicted to interact with the
extracellular cysteine residues on the P2Y12 receptor. In
this study we identified the reactive cysteine residues on the human
P2Y12 receptor by site-directed mutagenesis using pCMBS as
the thiol reagent. Cys97Ser and Cys175Ser mutants of the
P2Y12 receptor did not express when transfected
into Chinese hamster ovary (CHO-K1) cells, indicating the
essential nature of a disulfide bridge between these residues. The
Cys17Ser, Cys270Ser, and Cys17Ser/Cys270Ser double mutants had similar
median effective concentration (EC50) values for
ADP and 2-methylthio-ADP (2-MeSADP) when compared with the
wild-type P2Y12. Similarly, the median inhibitory
concentration (IC50) values for BzATP
(2',3'-O-(4- benzoylbenzoyl) adenosine 5'-triphosphate),
an antagonist of the P2Y12 receptor, also did not differ
dramatically among these mutants and the wild-type P2Y12
receptor. pCMBS inactivated the wild-type P2Y12 receptor in
a concentration-dependent manner, whereas it had no effect on the
P2Y1 receptor. Finally, pCMBS partially affected the
Gi coupling of Cys17Ser or Cys270Ser receptor mutants, but
had no effect on Cys17Ser/Cys270Ser P2Y12
receptor-mediated inhibition of adenylyl cyclase. These results
indicate that, unlike the P2Y1 receptor, which has 2 essential disulfide bridges linking its extracellular domains, the
P2Y12 receptor has 2 free cysteines in its extracellular
domains (Cys17 and Cys270), both of which are targets of thiol
reagents. We speculate that the active metabolites of clopidogrel and
CS-747 form disulfide bridges with both Cys17 and Cys270 in the
P2Y12 receptor, and thereby inactivate the receptor.
(Blood. 2003;101:3908-3914) Extracellular nucleotides act on cell-surface
receptors, known as P2 receptors, leading to a number of physiologic
responses including cardiac muscle contraction and platelet
aggregation.1 Adenosine triphosphate (ATP) and
adenosine diphosphate (ADP) are released from several sources in the
body, including purinergic nerve endings, platelets, chromaffin cells,
and endothelial cells.2 The P2 receptors are divided
mainly into 2 classes: P2X ligand-gated channels and P2Y receptors
coupled to heterotrimeric G proteins.3 Several members of
the P2X family and the P2Y family have been cloned.3-8 Of
the P2Y receptor subtypes characterized to date, most couple to
heterotrimeric guanosine 5c-triphosphate (GTP)-binding protein that
activates phospholipase C (Gq), but some couple to heterotrimeric GTP-binding protein that inhibits adenylyl cyclase (Gi). These Gi-coupled P2Y receptors
are found in platelets,9 C6 rat glioma
cells,10,11 and B10 microvascular endothelial cells.12
Of the G protein-coupled P2Y receptors, platelet ADP receptor coupled
to inhibition of adenylyl cyclase (P2Y12) is
expressed in platelets and in the brain,7,8 whereas the
platelet ADP receptor coupled to stimulation of phospholipase C
(P2Y1) receptor is expressed
ubiquitously.13 The genes for P2Y12 and
P2Y1 receptors are colocalized on chromosome
3q21-q2514 and share 22% sequence identity.7,8 The P2Y1 and the
P2Y12 receptors play an important role in the activation of
platelets, and coactivation of both of the receptors is essential for
ADP-induced activation of platelet fibrinogen
receptor.9,15,16 In platelets, these 2 receptors have
identical pharmacologic profiles (ADP and 2-MeSADP agonists; ATP and BzATP [2'-,3'-O-(4-benzoylbenzoyl) adenosine
5'-triphosphate] antagonists).17-20 An
antiplatelet drug, clopidogrel, is metabolized in the liver to an
active metabolite containing a free thiol group, which inactivates the
P2Y12 receptor through formation of a disulfide bridge with
extracellular cysteine residues.21-23 Another antiplatelet drug, CS-747, also neutralizes the P2Y12 receptor by the
same mechanism.24,25 In addition, the P2Y12
receptor is irreversibly antagonized by the thiol reagent
p-chloromercuribenzene sulfonic acid
(pCMBS).22,26,27
Most G protein-coupled receptors (GPCRs), including the P2Y receptors,
possess 2 conserved extracellular cysteine residues located on the
first and second extracellular loops (Figure
1). A disulfide bridge formed between
these 2 cysteines is essential for the function of a number of GPCRs,
including rhodopsin, the thyroid-stimulating
hormone-releasing hormone receptor, the thromboxane receptor,
the gonadotrophin-releasing hormone receptor, and the P2Y1
receptor.28-30 In addition to this essential disulfide
bridge between Cys124 in the first extracellular loop and Cys202 in the second extracellular loop of the P2Y1 receptor, Hoffmann et
al31 found an additional essential disulfide bridge
between 2 other extracellular cysteines (Cys42 in the amino terminal
and Cys296 in the third extracellular loop) of the P2Y1
receptor. Although the P2Y12 receptor also has these
corresponding cysteine residues (Cys17 and Cys270) in its extracellular
regions (Figure 1), the function of these cysteines has not been
investigated.
In this study, we evaluated the function of extracellular cysteine
residues of the P2Y12 receptor by site-directed mutagenesis and conclude that there is no essential disulfide bridge between Cys17
and Cys270. Furthermore, we conclude that thiol reagents such as pCMBS
can inactivate the P2Y12 receptor by targeting either Cys17
or Cys270 or both. Thus, we postulate that Cys17 and Cys270 are
possible targets of the antithrombotic drugs clopidogrel and CS-747
through the action of an active metabolite.
Materials
Construction of the P2Y12 expression plasmid
Site-directed mutagenesis All mutations were introduced into pcDNA3-HP2Y12 using the QuickChange site-directed mutagenesis kit from Stratagene. The resulting changes in oligonucleotides and the corresponding amino acids are shown in Table 1. Using Cys270Ser as a template and Cys17Ser mutation primers, a Cys17Ser/Cys270 double mutation was achieved by the same method. All mutations were confirmed by DNA sequencing.
Cell culture Chinese hamster ovary (CHO-K1) cells were grown in HAM F12 medium (Cellgro, Herndon, VA) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin/amphotericin at 37°C with 5% CO2. CHO-K1 cells transfected with wild-type or mutant P2Y12 receptors were grown in the same medium supplemented with 400 µg/mL hygromycin. Astrocytoma cells (1321N1) stably expressing the human P2Y1 receptor32 were grown in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin/amphotericin, and 500 µg/mL G418 (Cellgro) at 37°C with 5% CO2. Experiments were carried out in confluent cultures 2 days after plating in 6- or 12-well plates.Stable expression of human P2Y12 receptor in CHO-K1 cells The expression construct for the wild-type P2Y12 receptor (pcDNA3-HP2Y12) or for each of the P2Y12 site-directed mutants (Cys17Ser, Cys97Ser, Cys175Ser, Cys270Ser, and Cys17Ser/Cys270Ser) (1 µg) was used to transfect CHO-K1 cells using lipofectamine as described previously.33 CHO-K1 cells were also transfected with pcDNA3.1/Hygro(+) to serve as a mock control. The growth medium was replaced after 6 hours with fresh medium containing 400 µg/mL hygromycin. Stable transfectants were selected on medium containing 400 µg/mL hygromycin and screened for the expression of wild-type or mutant P2Y12 receptor by second messenger (cAMP) inhibition.FLAG-tag detection in CHO-K1 cells by immunofluorescence microscopy Cells were cultured in Lab-Tek Chamber Slide Culture Chambers overnight and washed twice with Tris (tris(hydroxymethyl)aminomethane)-buffered saline (TBS; 0.05 M Tris, 0.15 M NaCl, pH 7.4). Cells were fixed with freshly prepared methanol-acetone (1:1, using a glass vial) for one minute at room temperature, and then washed with TBS 4 times and incubated with anti-FLAG M2-FITC at 40 µg/mL in TBS at room temperature for 2 hours (gentle shaking in the dark). Cells were further washed twice with TBS, and 3 drops of component C of Slow Fade Light Antifade Kit were added and incubated for 10 minutes at room temperature. Finally, component C was washed away with TBS, and a small drop of component A was added, then covered with a cover slip, and examined using a Nikon Eclipse TE300 fluorescence microscope (Melville, NY).Cyclic AMP assay Cells were cultured in 6-well plates and labeled with 2 µL/mL [3H]-adenine (74 kBq/mL) for 4 hours or overnight at 37°C. The radiolabeling medium was replaced by fresh growth medium containing 1 mM IBMX (3-isobutyl-1-methylxanthine) and incubated for 10 minutes at 37°C. After stimulation with 20 µM forskolin for 1 minute, various concentrations of agonist and antagonist were added and incubated at 37°C for 10 minutes unless indicated. The reactions were terminated by addition of 1 M HCl containing 2000 cpm of [14C]-cAMP (2 GBq/mmol) as a recovery standard. Cyclic AMP levels were determined as described earlier32,34 and expressed as a percentage of total [3H]-adenine nucleotides. The median effective concentration (EC50)/median inhibitory concentration (IC50) values are calculated using Kaleidagraph 3.5 (Synergy Software, Reading, PA) fitting the curve to m1 + (m2 m1)/[1 + (m0/m3)m4],
where m0 is the difference between the maximal and minimal response, m1 is the minimal value of response, m2 is the maximal value
of response, m3 is the estimated EC50 or IC50,
and m4 is the slope. After fitting the curve, the calculated mean and
SE of EC50 or IC50 is given automatically by
the program.
Measurements of inositol phosphates Inositol phosphates were measured essentially as described.35,36 Confluent cultures of cells in 12-well plates were labeled with 1 µCi/mL (0.037 MBq/mL) myo-2-[3H] inositol in inositol-free DMEM for 24 hours. Labeled cells were washed once, the medium was replaced with 890 µL fresh inositol-free 20 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid)-buffered Eagle medium, pH 7.4, and the cells were incubated at 37°C for 30 minutes before proceeding; this step helped to reduce background levels of [3H] inositol phosphates, so that agonist-stimulated accumulation could be detected more easily. After incubation for 30 minutes at 37°C, 10 µL of 1 M LiCl was added to a final concentration of 10 mM, and the incubation continued for an additional 10 minutes. The cells were stimulated with 100 µL ADP at a final concentration of 10 µM for 15 minutes, and the reaction was terminated by aspiration of the medium, addition of 0.75 mL of 10 mM formic acid, and incubation at room temperature for 30 minutes. The solution containing the extracted inositol phosphates were neutralized by dilution with 3 mL of 10 mM NH4OH (yielding a final pH of 8-9) and then applied directly to a column containing 0.7 mL of the anion exchange resin, AG 1-X8, equilibrated with 40 mM ammonium formate. The column was washed with 4 mL of 40 mM ammonium formate, pH 5.0, to remove the free inositol and the glyceroinositol. Total inositol phosphates were eluted with 4 mL of 2 M ammonium formate, pH 5.0. The eluate (1 mL) was removed and counted with 9 mL of scintillation fluid.Statistical analysis All experiments were performed at least 3 times in duplicate. Data are expressed as means ± SE. Statistical significance was determined using the Student t test and significance was designated to P values less than .05.
Human platelets express 2 P2Y receptors, the P2Y1 and P2Y12 receptors,7,8,13 and each have 4 conserved extracellular cysteines capable of forming 2 disulfide bridges to stabilize the 3-dimensional structure of the receptor (Figure 1). In the case of the P2Y1 receptor, Cys124 in the first extracellular loop forms a disulfide bridge with Cys202 in the second extracellular loop, which is essential for the function of the receptor.31 In addition, the P2Y1 receptor has an additional disulfide bridge between Cys42 in the amino terminus and Cys296 in the third extracellular loop.31 Disruption of this bridge by site-directed mutagenesis of either Cys42 or Cys296 results in dramatic loss of the ability of the agonist to activate the receptor.31 As both the P2Y1 and the P2Y12 receptors have similar pharmacologic profiles in platelets,9,14,18,20 we first sought to determine whether the P2Y12 receptor also has 2 essential disulfide bridges between its 4 conserved extracellular cysteine residues. Secondly, we wanted to identify the cysteines in the P2Y12 receptor that interact with thiol reagents. To achieve these objectives, we constructed an expression plasmid for the P2Y12 receptor and mutated each of the 4 cysteines in the P2Y12 receptor (Cys17, Cys97, Cys175, and Cys270) to serines. In addition, we generated a double mutant of Cys17Ser and Cys270Ser by site-directed mutagenesis. Stable expression of wild-type and mutant human P2Y12 receptors in CHO-K1 cells CHO-K1 cells were transfected with the P2Y12 wild-type receptor, and clones resistant to 400 µg/mL hygromycin were selected. We screened our clones based on their response to 10 µM ADP in the adenylyl cyclase inhibition assay. From 16 cell clones, 1 wild-type clone was selected and designated P2Y12WT. The expression of P2Y12 wild type on the surface of CHO-K1 cells was also confirmed by immunofluorescence microscopy using a monoclonal antibody directed against the FLAG tag at the N-terminus of the receptor (Figure 2). Unfortunately, this monoclonal antibody was not useful in detecting the receptor expression by the enzyme-linked immunosorbent assay (ELISA) method.
Similarly, CHO-K1 cells transfected with expression constructs for P2Y12 mutants Cys17Ser and Cys270Ser were grown in the presence of hygromycin and screened by cAMP inhibition assay. There were 2 cell clones designated P2Y12Cys17Ser and P2Y12Cys270Ser selected from 15 and 12 cell clones, respectively. In contrast to the P2Y12 wild type and mutants Cys17Ser, Cys270Ser, and Cys17Ser/Cys270Ser, no positive clone was found after screening 61 cell clones stably transfected with Cys97Ser and 49 cell clones stably transfected with Cys175Ser. Immunofluorescence experiments with the antibody against the FLAG tag failed to detect any receptor expression on these cell clones. These results were not totally unexpected as similar results were obtained when Cys124 and Cys202 in the P2Y1 receptor were mutated to serines.31 These results indicate that a disulfide bridge between Cys97 and Cys175 might be essential for the receptor expression as is the case with the P2Y1 receptor.31 However, it is also possible that a cysteine is required at both of these positions for the receptor expression. Finally, one cell clone, designated P2Y12Cys17Ser/Cys270Ser, was selected from 12 hygromycin-resistant clones by a similar method from CHO-K1 cells transfected with expression constructs for the P2Y12 receptor double-mutant Cys17Ser/Cys270Ser. Characterization of cloned human P2Y12 receptor and the mutants expressed in CHO-K1 cells The mutation of Cys42 and Cys296 in the P2Y1 receptor leads to dramatically diminished responses to the agonist.31 We evaluated the function of the corresponding cysteines in the P2Y12 receptor with Cys17Ser mutant and Cys270Ser mutant and compared them with the wild-type P2Y12 receptor. The wild-type P2Y12 receptor, the P2Y12Cys17Ser, or the P2Y12Cys270Ser mutant caused similar inhibition of forskolin-stimulated adenylyl cyclase upon stimulation by ADP (Figure 3A) or 2-MeSADP (Figure 3B) in a concentration-dependent manner. The EC50 values for these agonists are comparable in the wild-type and mutant P2Y12 receptors (Table 2). We generated a cell line stably expressing the double-mutant P2Y12Cys17Ser/Cys270Ser and evaluated its ability to respond to the agonists. As shown in Figure 3, this double mutant also has similar EC50 values compared with the wild-type receptor (Table 2). These results indicate that mutations at Cys17 and/or Cys270 did not considerably alter the function or coupling of the P2Y12 receptor. Similar mutations in the P2Y1 receptor dramatically increased the EC50 values of the agonists.31 Thus, we conclude that, unlike in the P2Y1 receptor, a disulfide bridge between the cysteines in the amino terminus (Cys17) and the third extracellular loop (Cys270) is not essential for the function of the P2Y12 receptor.
Effect of antagonist on the wild-type and mutant P2Y12 receptors Human platelets express both the P2Y1 and P2Y12 receptors that contribute to various agonist-induced physiologic responses.9,15,16,37 BzATP inhibits both the Ca2+- and cAMP-dependent intracellular signaling pathways of ADP in endothelial cells and platelets through antagonism of the P2Y1 and P2Y12 receptors.17 We evaluated the effect of this nonselective antagonist on the wild-type and mutant P2Y12 receptors. As shown in Figure 4, BzATP blocks 1 µM ADP-induced inhibition of adenylyl cyclase in CHO-K1 cells stably expressing P2Y12WT, P2Y12Cys17Ser, P2Y12Cys270Ser, or P2Y12Cys17Ser/Cys270Ser in a concentration-dependent manner. The IC50 values for the antagonism by BzATP are 116 ± 23 µM (wild type), 85 ± 6 µM (P2Y12Cys17Ser), 137 ± 15 µM (P2Y12Cys270Ser), and 58 ± 5 µM (P2Y12Cys17Ser/Cys270Ser). Compared with the wild type, the concentration-response curves of Cys17Ser/Cys270Ser mutant slightly shifted to the left, suggesting that double mutation renders the receptor more sensitive to the antagonist. It is possible that these 2 extracellular cysteines play a role in the binding of the BzATP and thereby alter the sensitivity of the receptor to the antagonist.
Effects of pCMBS on the function of the P2Y receptors A critical role of cysteine residues in the function of the platelet ADP receptor has been suggested by the ability of pCMBS, a nonpenetrating thiol reagent, to abolish ADP responses in platelets.20,26 It was also shown that pCMBS affects the binding of the agonist to the ADP receptor mediating the adenylyl cyclase inhibition response.22,27 As both the P2Y1 and P2Y12 receptors have 4 conserved extracellular cysteine residues (Figure 1), we evaluated the effect of pCMBS on these 2 platelet P2Y receptors. As shown in Figure 5, pCMBS blocked ADP-induced inhibition of forskolin-stimulated adenylyl cyclase in the cells expressing the human P2Y12 receptor in a concentration-dependent manner, whereas it did not inhibit agonist-induced inositol phosphate formation in the cells stably expressing the P2Y1 receptor. The effect of pCMBS on the human P2Y12 receptor is consistent with the data published by Savi et al.22 Thus, pCMBS inactivates the P2Y12 receptor but not the P2Y1 receptor. As this thiol reagent is cell-impermeable and covalently binds to the free thiol groups, we predict that the Cys17 and Cys270 in the P2Y12 receptor exist as free cysteines and may be the target of pCMBS. On the other hand, the P2Y1 receptor does not have free extracellular cysteines, as the corresponding cysteines (Cys42 and Cys296) form an essential disulfide bridge, and hence is insensitive to pCMBS. Thus, we conclude that the P2Y12 receptor does not have a disulfide bridge between Cys17 and Cys270 and that these residues are free cysteines in the native receptor and may be the target of the thiol reagents.
The sensitivity of the P2Y12 receptor to thiol reagents explains the mechanism of clopidogrel.22,23 Since its approval in 1988, clopidogrel has been broadly used as an antiplatelet drug.21 Although the P2Y12 receptor was thought to be the target of clopidogrel,38 its mechanism of action remained unclear until recently.22,23,39 P2Y12 receptors play an essential role in ADP-induced platelet aggregation,40 and, hence, the P2Y12 receptor-defective patients41-43 and mice deficient in the P2Y12 receptor have abnormal platelet aggregation.16 Savi et al23 proposed that the extracellular cysteine on P2Y12 was modified by formation of a disulfide bridge with the thiol group on the active metabolite of clopidogrel. Similarly, CS-747 was also predicted to target the extracellular cysteines in the P2Y12 receptor through conversion to an active metabolite in the liver.24,25 Effects of pCMBS on the wild-type and mutant P2Y12 receptors The active metabolite of clopidogrel has to be purified into an active enantiomer metabolite from the liver microsomes and is highly unstable.22,23 Hence, we used pCMBS as a tool to identify the reactive cysteine residue on the P2Y12 receptor using ADP-induced inhibition of adenylyl cyclase assay on CHO-K1 cells stably expressing the wild-type and mutant P2Y12 receptors. As shown in Figure 6, pCMBS (20 µM) significantly reversed the inhibitory effects of 10 µM ADP on adenylyl cyclase in CHO-K1 cells stably expressing wild type and Cys17Ser (41 ± 5 vs 83 ± 12 and 37.1 ± 2.7 vs 74 ± 3, respectively). Although pCMBS reversed the effect of ADP in the P2Y12Cys270Ser mutant, the effect was not as dramatic (39.4 ± 2.1 vs 57.3 ± 2.3). Finally, pCMBS did not reverse the ADP-induced inhibition of adenylyl cyclase in the cells expressing the double-mutant P2Y12Cys17Ser/Cys270Ser (46.2 ± 2.9 vs 51 ± 3, mean ± SE, P < .05). These results indicate that both Cys17 and Cys270 are the targets of pCMBS. The primary target appears to be Cys270, as the effect of pCMBS appears to be more dramatic on the P2Y12Cys17Ser mutant than on the P2Y12Cys270Ser mutant. However, a small effect on the single Cys270Ser mutant shows that even Cys17 is a target of the thiol reagent. Thus, we conclude that both Cys17 and Cys270 are the targets of the thiol reagents as they exist as the free cysteine residues in the native receptor in platelets.
As the active metabolites of clopidogrel and CS-747 form a disulfide bridge with the free thiol groups on the P2Y12 receptor, we postulate that Cys17 and Cys270 are the targets of the metabolites of these drugs. It should be noted that in order to achieve a complete effect, a thiol reagent should block both of the cysteine residues. Thus partial inhibition, such as that seen in humans when lower doses of clopidogrel are used,21,44 could be due to incomplete blockade of the Cys17 and Cys270 on the platelet P2Y12 receptor. Our results indicate that only one disulfide bridge is formed among the 4 extracellular cysteines and that 2 free extracellular cysteines are the targets of clopidogrel. Among the 4 extracellular cysteines on the platelet P2Y1 receptor, 2 disulfide bridges are formed, and both of them are essential to receptor function.31 Clopidogrel specifically targets the P2Y12 receptor.39,45 Our results successfully explain the specificity of clopidogrel on P2Y12 rather than P2Y1. As is the case with pCMBS, we believe that lack of free cysteines in the P2Y1 receptor makes it insensitive to clopidogrel. As the homology and positioning of the cysteine residues in the P2Y12 receptor relative to the P2Y1 receptor suggest a disulfide bond should also exist in the P2Y12 receptor, it is possible that there may be a dynamic redox exchange operating between Cys17 and Cys270. Thus, a P2Y12 receptor-specific disulfide reductase operating in the external oxidative cellular environment could generate free cysteine residues from a disulfide bridge between Cys17 and Cys270 that could then be targeted by the thiol reagents. There is considerable evidence to suggest that the metabolites of clopidogrel and CS-747 have specificity for the P2Y12 receptor. Although both P2Y1 and P2Y12 receptors have similar pharmacologic profiles, only the P2Y12 receptor is affected by the metabolites of clopidogrel and CS-747. This observation indicates that the specific ligand-binding pocket of the P2Y12 receptor might have only one of the cysteine residues (either Cys17 or Cys270) that would be accessible for modification by the metabolite. However, such modification of a single cysteine residue by the active metabolite of clopidogrel might be sufficient to block the binding of the agonist. It is possible that pCMBS did not achieve complete inhibition because of its small size in the single mutants, whereas clopidogrel metabolite might achieve this by interacting with only one of the cysteines because of its larger size. Hence, we would speculate that the active metabolites of clopidogrel and CS-747 might interact with only one of the cysteine residues (very likely Cys270) in the P2Y12 receptor to cause blockade of agonist binding. Unlike the thiol reagent pCMBS, the active metabolites of clopidogrel or CS-747, with a free thiol group, could also break disulfide bridges. Thus, these active metabolites could break the essential disulfide bridge between Cys97 and Cys175 of the P2Y12 receptor, thereby forming a separate disulfide bridge with each of these residues. Such action could result in an inactive receptor as the naturally formed disulfide bridge maintains the receptor in a conformation required for agonist binding. However, we believe that this is an unlikely mechanism. If the clopidogrel metabolite can break an existing disulfide bridge, then we expect that it also should inactivate a number of G protein-coupled receptors, including the P2Y1 receptor, by the same mechanism. Even if it is argued that the metabolite depends on an agonist binding pocket, we expect that the P2Y1 receptor should also be inactivated by this metabolite. However, despite having the same agonist profile, the P2Y1 receptor is insensitive to clopidogrel. In conclusion, we have shown that unlike the P2Y1 receptor, which has 2 essential disulfide bridges in its extracellular domains, the P2Y12 receptor has 2 free cysteines in its extracellular domains (Cys17 and Cys270), both of which are the targets of thiol reagents. We predict that the P2Y1 receptor is insensitive to the thiol reagents and to the active metabolites of clopidogrel and CS-747 because of the lack of these free cysteines in the extracellular domains. Thus, we speculate that the active metabolites of clopidogrel and CS-747 form disulfide bridges with Cys17 and/or Cys270 in the P2Y12 receptor and thereby inactivate the receptor.
We thank Ms Mayosha Mendis for her technical assistance and Drs James L. Daniel, Barrie Ashby, A. Koneti Rao, Lee-Yuan Liu-Chen, Fujio Sekiya, and Todd M. Quinton, Temple University Medical School, for critically reading the manuscript.
Submitted October 18, 2002; accepted December 18, 2002.
Prepublished online as Blood First Edition Paper, January 30, 2003; DOI 10.1182/blood-2002-10-3027.
Supported by research grants HL60683 and HL64943 from the National Institutes of Health (S.P.K.). R.T.D. is supported by training grant T32 HL07777 from the National Institutes of Health.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Satya P. Kunapuli, Department of Physiology, Temple University School of Medicine, Room 224 OMS, 3420 N Broad St, Philadelphia, PA 19140; e-mail: spk{at}temple.edu.
1. Burnstock G. A basis for distinguishing two types of purinergic receptors. In: Straub RW,Bolis L, eds. Cell Membrane Receptors for Drugs and Hormones: a Multidisciplinary Approach. New York, NY: Raven Press; 1978:107-118. 2. Gordon J. Extracellular ATP: effects, sources and fates. Biochem J. 1986;233:309-319[Medline] [Order article via Infotrieve]. 3. Fredholm BB, Abbracchio MP, Burnstock G, et al. Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci. 1997;18:79-82[Medline] [Order article via Infotrieve].
4.
Zhang FL, Luo L, Gustafson E, et al.
P2Y(13): identification and characterization of a novel Galphai-coupled ADP receptor from human and mouse.
J Pharmacol Exp Ther.
2002;301:705-713
5.
Communi D, Govaerts C, Parmentier M, Boeynaems J-M.
Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase.
J Biol Chem.
1997;272:31969-31973
6.
Communi D, Gonzalez NS, Detheux M, et al.
Identification of a novel human ADP receptor coupled to G(i).
J Biol Chem.
2001;276:41479-41485
7.
Zhang FL, Luo L, Gustafson E, et al.
ADP is the cognate ligand for the orphan G-protein coupled receptor SP1999.
J Biol Chem.
2001;276:8608-8615 8. Hollopeter J, Jantzen H-M, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202-207[CrossRef][Medline] [Order article via Infotrieve]. 9. Kunapuli SP. Multiple P2 receptor subtypes on platelets: a new interpretation of their function. Trends Pharmacol Sci. 1998;19:391-394[CrossRef][Medline] [Order article via Infotrieve].
10.
Boyer JL, Lazarowski ER, Chen X-H, Harden TK.
Identification of a P2Y-purinergic receptor that inhibits adenylyl cyclase.
J Pharmacol Exp Ther.
1993;267:1140-1146 11. Planet I, Merle M, Labouesse J. ADP and, indirectly, ATP are potent inhibitors of cAMP production in intact isopreterenol-stimulated C6 glioma cells. Biochem Biophys Res Commun. 1989;163:1150-1157[CrossRef][Medline] [Order article via Infotrieve]. 12. Feolde E, Vigne P, Breittmayer JP, Frelin C. ATP, a partial agonist of atypical P2y purinoceptors in rat brain capillary endothelial cells. Brit J Pharmacol. 1995;115:1199-1203[Medline] [Order article via Infotrieve]. 13. Ayyanathan K, Webb TE, Sandhu AK, Athwal RS, Barnard EA, Kunapuli SP. Cloning and chromosomal localization of human P2Y1 purinoceptor. Biochem Biophys Res Commun. 1996;218:783-788[CrossRef][Medline] [Order article via Infotrieve]. 14. Ayyanathan K, Naylor SL, Kunapuli SP. Structural characterization and fine chromosomal mapping of the human P2Y1 purinergic receptor gene (P2YR1). Som Cell Mol Genet. 1996;22:419-424[CrossRef][Medline] [Order article via Infotrieve]. 15. Fabre JE, Nguyen M, Latour A, et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med. 1999;5:1199-1202[CrossRef][Medline] [Order article via Infotrieve]. 16. Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001;107:1591-1598[Medline] [Order article via Infotrieve]. 17. Vigne P, Hechler B, Gachet C, Breittmayer JP, Frelin C. Benzoyl ATP is an antagonist of rat and human P2Y1 receptors and of platelet aggregation. Biochem Biophys Res Commun. 1999;256:94-97[CrossRef][Medline] [Order article via Infotrieve]. 18. Hourani SMO, Hall DA. Receptors for ADP on human platelets. Trends in Pharmacol Sci. 1994;15:103-108. 19. Kunapuli SP. Molecular physiology of platelet ADP receptors. Drug Dev Res. 1998;45:135-139[CrossRef]. 20. Mills DCB. ADP receptor in platelets. Thromb Haemost. 1996;76:835-856[Medline] [Order article via Infotrieve]. 21. Bennett JS. Novel platelet inhibitors. Annu Rev Med. 2001;52:161-184[CrossRef][Medline] [Order article via Infotrieve]. 22. Savi P, Labouret C, Delesque N, Guette F, Lupker J, Herbert JM. P2Y12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun. 2001;283:379-383[CrossRef][Medline] [Order article via Infotrieve]. 23. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891-896[Medline] [Order article via Infotrieve]. 24. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129:1439-1446[CrossRef][Medline] [Order article via Infotrieve]. 25. Sugidachi A, Asai F, Yoneda K, et al. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br J Pharmacol. 2001;132:47-54[CrossRef][Medline] [Order article via Infotrieve].
26.
Rao AK, Kowalska MA.
ADP-induced platelet shape change and mobilization of cytoplasmic ionized calcium are mediated by distinct binding sites on platelets: 5'-p-fluorosulfonylbenzoyladenosine is a weak platelet agonist.
Blood.
1987;70:751-756 27. Cristalli G, Mills DCB. Identification of a receptor for ADP on blood platelets by photoaffinity labelling. Biochem J. 1993;291:875-881[Medline] [Order article via Infotrieve].
28.
Cook JV, Eidne KA.
An intramolecular disulfide bond between conserved extracellular cysteines in the gonadotropin-releasing hormone receptor is essential for binding and activation.
Endocrinology.
1997;138:2800-2806
29.
D'Angelo DD, Eubank JJ, Davis MG, Dorn GW II.
Mutagenic analysis of platelet thromboxane receptor cysteines: roles in ligand binding and receptor-effector coupling.
J Biol Chem.
1996;271:6233-6240
30.
Ji TH, Grossmann M, Ji I.
G protein-coupled receptors: I. Diversity of receptor-ligand interactions.
J Biol Chem.
1998;273:17299-17302
31.
Hoffmann C, Moro S, Nicholas RA, Harden TK, Jacobson KA.
The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes.
J Biol Chem.
1999;274:14639-14647 32. Jin J, Tomlinson W, Kirk IP, Kim YB, Humphries RG, Kunapuli SP. The C6-2B glioma cell P2Y(AC) receptor is pharmacologically and molecularly identical to the platelet P2Y(12) receptor. Br J Pharmacol. 2001;133:521-528[CrossRef][Medline] [Order article via Infotrieve].
33.
Akbar GKM, Dasari VR, Webb TE, et al.
Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells.
J Biol Chem.
1996;271:18363-18367
34.
Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP.
Molecular basis for ADP-induced platelet activation: I. Evidence for three distinct ADP receptors on platelets.
J Biol Chem.
1998;273:2024-2029
35.
Kunapuli P, Lawson JA, Rokach J, Fitzgerald GA.
Functional characterization of the ocular prostaglandin F2 36. Filtz TM, Li Q, Boyer JL, Nicholas RA, Harden TK. Expression of a cloned P2y purinergic receptor that couples to phospholipase C. Mol Pharmacol. 1994;46:8-14[Abstract]. 37. Leon C, Hechler B, Freund M, et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice [see comments]. J Clin Invest. 1999;104:1731-1737[Medline] [Order article via Infotrieve].
38.
Mills DCB, Puri RN, Hu C-J, et al.
Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.
Atheroscler Thromb.
1992;12:430-436
39.
Geiger J, Brich J, Honig-Liedl P, et al.
Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel.
Arterioscler Thromb Vasc Biol.
1999;19:2007-2011
40.
Jin J, Kunapuli SP.
Co-activation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.
Proc Natl Acad Sci U. S. A.
1998;95:8070-8074
41.
Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM.
Identification of a new congenital defect of platelet aggregation characterized by severe impairment of platelet responses to adenosine 5'-diphosphate.
Blood.
1992;80:2787-2796 42. Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol. 2000;20:E101-E106. 43. Nurden P, Savi P, Heilmann E, et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J Clin Invest. 1995;95:1612-1622[Medline] [Order article via Infotrieve]. 44. Seyfarth HJ, Koksch M, Roethig G, et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J. 2002;143:118-123[CrossRef][Medline] [Order article via Infotrieve]. 45. Gachet C, Stierle A, Cazenave JP, et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol. 1990;40:229-238[CrossRef][Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  N. F. Ford Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic? J. Clin. Pharmacol., May 1, 2009; 49(5): 506 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nishiya, K. Hagihara, T. Ito, M. Tajima, S.-i. Miura, A. Kurihara, N. A. Farid, and T. Ikeda Mechanism-Based Inhibition of Human Cytochrome P450 2B6 by Ticlopidine, Clopidogrel, and the Thiolactone Metabolite of Prasugrel Drug Metab. Dispos., March 1, 2009; 37(3): 589 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Savi, J.-L. Zachayus, N. Delesque-Touchard, C. Labouret, C. Herve, M.-F. Uzabiaga, J.-M. Pereillo, J.-M. Culouscou, F. Bono, P. Ferrara, et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts PNAS, July 18, 2006; 103(29): 11069 - 11074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Turgeon, C. Pharand, and V. Michaud Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism Can. Med. Assoc. J., June 6, 2006; 174(12): 1729 - 1729. [Full Text] [PDF]
|
|
|
|
 |
|
 B. T. Ivandic, P. Schlick, P. Staritz, K. Kurz, H. A. Katus, and E. Giannitsis Determination of Clopidogrel Resistance by Whole Blood Platelet Aggregometry and Inhibitors of the P2Y12 Receptor Clin. Chem., March 1, 2006; 52(3): 383 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Ding, S. Kim, and S. P. Kunapuli Identification of a Potent Inverse Agonist at a Constitutively Active Mutant of Human P2Y12 Receptor Mol. Pharmacol., January 1, 2006; 69(1): 338 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. von Beckerath, D. Taubert, G. Pogatsa-Murray, E. Schomig, A. Kastrati, and A. Schomig Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial Circulation, November 8, 2005; 112(19): 2946 - 2950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Giniatullin, S. N. Grishin, E. R. Sharifullina, A. M. Petrov, A. L. Zefirov, and R. A. Giniatullin Reactive oxygen species contribute to the presynaptic action of extracellular ATP at the frog neuromuscular junction J. Physiol., May 15, 2005; 565(1): 229 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Nguyen, J. G. Diodati, and C. Pharand Resistance to clopidogrel: A review of the evidence J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1157 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Ding, F. Tuluc, K. R. Bandivadekar, L. Zhang, J. Jin, and S. P. Kunapuli Arg333 and Arg334 in the COOH terminus of the human P2Y1 receptor are crucial for Gq coupling Am J Physiol Cell Physiol, March 1, 2005; 288(3): C559 - C567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Krotz, H.-Y. Sohn, and U. Pohl Reactive Oxygen Species: Players in the Platelet Game Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 1988 - 1996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Shankar, S. Murugappan, S. Kim, J. Jin, Z. Ding, K. Wickman, and S. P. Kunapuli Role of G protein-gated inwardly rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses Blood, September 1, 2004; 104(5): 1335 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Richter, T. E. Murdter, G. Heinkele, J. Pleiss, S. Tatzel, M. Schwab, M. Eichelbaum, and U. M. Zanger Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 189 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lahav, E. M. Wijnen, O. Hess, S. W. Hamaia, D. Griffiths, M. Makris, C. G. Knight, D. W. Essex, and R. W. Farndale Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin {alpha}2{beta}1 Blood, September 15, 2003; 102(6): 2085 - 2092. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
(PGF2